A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults

Abstract Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection (LRTI) in infants worldwide. Nirsevimab, an extended half‐life monoclonal antibody against RSV, is approved in China for the prevention of RSV lower respiratory tract disease in infants; however, glo...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaomeng Mao, Xiaohan Hua, Chengyi Wu, Xiaoyun Ge, Jie Zhang, Xiaojie Wu, Robert J. Kubiak, Ulrika Wählby Hamrén, Tonya Villafana, Georgios Christou, Jannine Green, Therese Takas, Yuwen Jin
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.70095
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832589780647411712
author Xiaomeng Mao
Xiaohan Hua
Chengyi Wu
Xiaoyun Ge
Jie Zhang
Xiaojie Wu
Robert J. Kubiak
Ulrika Wählby Hamrén
Tonya Villafana
Georgios Christou
Jannine Green
Therese Takas
Yuwen Jin
author_facet Xiaomeng Mao
Xiaohan Hua
Chengyi Wu
Xiaoyun Ge
Jie Zhang
Xiaojie Wu
Robert J. Kubiak
Ulrika Wählby Hamrén
Tonya Villafana
Georgios Christou
Jannine Green
Therese Takas
Yuwen Jin
author_sort Xiaomeng Mao
collection DOAJ
description Abstract Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection (LRTI) in infants worldwide. Nirsevimab, an extended half‐life monoclonal antibody against RSV, is approved in China for the prevention of RSV lower respiratory tract disease in infants; however, global nirsevimab trials did not enroll Chinese infants. To inform the investigation of nirsevimab for the prevention of RSV LRTI in Chinese infants, this Phase I, randomized, placebo‐controlled trial evaluated the pharmacokinetics (PK) and safety of nirsevimab in healthy Chinese adults. Participants were randomized 3:1 to a single 300 mg intramuscular dose of nirsevimab or placebo and were followed through 150 days post‐dose. Serum nirsevimab concentrations were measured and PK parameters of maximum serum concentration (Cmax), time to maximum concentration (tmax), and area under the concentration‐time curve from time 0 to Day 150 (AUC0–150) were estimated. Treatment emergent adverse events (AEs), clinical laboratory data, and vital signs were evaluated. Overall, 24 participants were randomized to nirsevimab (n = 18) or placebo (n = 6). Nirsevimab geometric mean (coefficient of variation [%CV]) Cmax was 46.9 (21.7) μg/mL, median (range) tmax was 7.0 (4.9, 29.9) days, and geometric mean (%CV) AUC0–150 was 4210.6 (13.6) μg·day/mL. Treatment‐emergent AEs (all Grade 1 or Grade 2 in severity) were reported in 5/18 (27.8%) nirsevimab recipients and 2/6 (33.3%) placebo recipients. No serious AEs, new onset chronic disease, or deaths were reported. Overall, safety and PK outcomes were consistent with those observed in healthy adults in the USA, with no new safety concerns.
format Article
id doaj-art-972c0e554c4545ea83401044b188263c
institution Kabale University
issn 1752-8054
1752-8062
language English
publishDate 2025-01-01
publisher Wiley
record_format Article
series Clinical and Translational Science
spelling doaj-art-972c0e554c4545ea83401044b188263c2025-01-24T08:17:46ZengWileyClinical and Translational Science1752-80541752-80622025-01-01181n/an/a10.1111/cts.70095A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adultsXiaomeng Mao0Xiaohan Hua1Chengyi Wu2Xiaoyun Ge3Jie Zhang4Xiaojie Wu5Robert J. Kubiak6Ulrika Wählby Hamrén7Tonya Villafana8Georgios Christou9Jannine Green10Therese Takas11Yuwen Jin12Clinical Pharmacology Research Center, Huashan Hospital Fudan University Shanghai ChinaClinical Development, Respiratory & Immunology, R&D China AstraZeneca Shanghai ChinaBiometrics, R&D China AstraZeneca Shanghai ChinaClinical Safety, R&D China AstraZeneca Shanghai ChinaDevelopment Operations, R&D China AstraZeneca Shanghai ChinaClinical Pharmacology Research Center, Huashan Hospital Fudan University Shanghai ChinaClinical Pharmacology and Quantitative Pharmacology, R&D AstraZeneca Gaithersburg Maryland USAClinical Pharmacology and Quantitative Pharmacology, R&D AstraZeneca Gothenburg SwedenClinical Development, Vaccines and Immune Therapies, Biopharmaceuticals R&D AstraZeneca Gaithersburg Maryland USAPatient Safety, Chief Medical Office, R&D AstraZeneca Gaithersburg Maryland USAGlobal Clinical Operations, R&D AstraZeneca Macclesfield UKClinical Development, Vaccines and Immune Therapies, Biopharmaceuticals R&D AstraZeneca Gaithersburg Maryland USAClinical Pharmacology, R&D China AstraZeneca Shanghai ChinaAbstract Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection (LRTI) in infants worldwide. Nirsevimab, an extended half‐life monoclonal antibody against RSV, is approved in China for the prevention of RSV lower respiratory tract disease in infants; however, global nirsevimab trials did not enroll Chinese infants. To inform the investigation of nirsevimab for the prevention of RSV LRTI in Chinese infants, this Phase I, randomized, placebo‐controlled trial evaluated the pharmacokinetics (PK) and safety of nirsevimab in healthy Chinese adults. Participants were randomized 3:1 to a single 300 mg intramuscular dose of nirsevimab or placebo and were followed through 150 days post‐dose. Serum nirsevimab concentrations were measured and PK parameters of maximum serum concentration (Cmax), time to maximum concentration (tmax), and area under the concentration‐time curve from time 0 to Day 150 (AUC0–150) were estimated. Treatment emergent adverse events (AEs), clinical laboratory data, and vital signs were evaluated. Overall, 24 participants were randomized to nirsevimab (n = 18) or placebo (n = 6). Nirsevimab geometric mean (coefficient of variation [%CV]) Cmax was 46.9 (21.7) μg/mL, median (range) tmax was 7.0 (4.9, 29.9) days, and geometric mean (%CV) AUC0–150 was 4210.6 (13.6) μg·day/mL. Treatment‐emergent AEs (all Grade 1 or Grade 2 in severity) were reported in 5/18 (27.8%) nirsevimab recipients and 2/6 (33.3%) placebo recipients. No serious AEs, new onset chronic disease, or deaths were reported. Overall, safety and PK outcomes were consistent with those observed in healthy adults in the USA, with no new safety concerns.https://doi.org/10.1111/cts.70095
spellingShingle Xiaomeng Mao
Xiaohan Hua
Chengyi Wu
Xiaoyun Ge
Jie Zhang
Xiaojie Wu
Robert J. Kubiak
Ulrika Wählby Hamrén
Tonya Villafana
Georgios Christou
Jannine Green
Therese Takas
Yuwen Jin
A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults
Clinical and Translational Science
title A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults
title_full A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults
title_fullStr A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults
title_full_unstemmed A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults
title_short A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults
title_sort phase i randomized placebo controlled trial to evaluate the pharmacokinetics safety and tolerability of nirsevimab in healthy chinese adults
url https://doi.org/10.1111/cts.70095
work_keys_str_mv AT xiaomengmao aphaseirandomizedplacebocontrolledtrialtoevaluatethepharmacokineticssafetyandtolerabilityofnirsevimabinhealthychineseadults
AT xiaohanhua aphaseirandomizedplacebocontrolledtrialtoevaluatethepharmacokineticssafetyandtolerabilityofnirsevimabinhealthychineseadults
AT chengyiwu aphaseirandomizedplacebocontrolledtrialtoevaluatethepharmacokineticssafetyandtolerabilityofnirsevimabinhealthychineseadults
AT xiaoyunge aphaseirandomizedplacebocontrolledtrialtoevaluatethepharmacokineticssafetyandtolerabilityofnirsevimabinhealthychineseadults
AT jiezhang aphaseirandomizedplacebocontrolledtrialtoevaluatethepharmacokineticssafetyandtolerabilityofnirsevimabinhealthychineseadults
AT xiaojiewu aphaseirandomizedplacebocontrolledtrialtoevaluatethepharmacokineticssafetyandtolerabilityofnirsevimabinhealthychineseadults
AT robertjkubiak aphaseirandomizedplacebocontrolledtrialtoevaluatethepharmacokineticssafetyandtolerabilityofnirsevimabinhealthychineseadults
AT ulrikawahlbyhamren aphaseirandomizedplacebocontrolledtrialtoevaluatethepharmacokineticssafetyandtolerabilityofnirsevimabinhealthychineseadults
AT tonyavillafana aphaseirandomizedplacebocontrolledtrialtoevaluatethepharmacokineticssafetyandtolerabilityofnirsevimabinhealthychineseadults
AT georgioschristou aphaseirandomizedplacebocontrolledtrialtoevaluatethepharmacokineticssafetyandtolerabilityofnirsevimabinhealthychineseadults
AT janninegreen aphaseirandomizedplacebocontrolledtrialtoevaluatethepharmacokineticssafetyandtolerabilityofnirsevimabinhealthychineseadults
AT theresetakas aphaseirandomizedplacebocontrolledtrialtoevaluatethepharmacokineticssafetyandtolerabilityofnirsevimabinhealthychineseadults
AT yuwenjin aphaseirandomizedplacebocontrolledtrialtoevaluatethepharmacokineticssafetyandtolerabilityofnirsevimabinhealthychineseadults
AT xiaomengmao phaseirandomizedplacebocontrolledtrialtoevaluatethepharmacokineticssafetyandtolerabilityofnirsevimabinhealthychineseadults
AT xiaohanhua phaseirandomizedplacebocontrolledtrialtoevaluatethepharmacokineticssafetyandtolerabilityofnirsevimabinhealthychineseadults
AT chengyiwu phaseirandomizedplacebocontrolledtrialtoevaluatethepharmacokineticssafetyandtolerabilityofnirsevimabinhealthychineseadults
AT xiaoyunge phaseirandomizedplacebocontrolledtrialtoevaluatethepharmacokineticssafetyandtolerabilityofnirsevimabinhealthychineseadults
AT jiezhang phaseirandomizedplacebocontrolledtrialtoevaluatethepharmacokineticssafetyandtolerabilityofnirsevimabinhealthychineseadults
AT xiaojiewu phaseirandomizedplacebocontrolledtrialtoevaluatethepharmacokineticssafetyandtolerabilityofnirsevimabinhealthychineseadults
AT robertjkubiak phaseirandomizedplacebocontrolledtrialtoevaluatethepharmacokineticssafetyandtolerabilityofnirsevimabinhealthychineseadults
AT ulrikawahlbyhamren phaseirandomizedplacebocontrolledtrialtoevaluatethepharmacokineticssafetyandtolerabilityofnirsevimabinhealthychineseadults
AT tonyavillafana phaseirandomizedplacebocontrolledtrialtoevaluatethepharmacokineticssafetyandtolerabilityofnirsevimabinhealthychineseadults
AT georgioschristou phaseirandomizedplacebocontrolledtrialtoevaluatethepharmacokineticssafetyandtolerabilityofnirsevimabinhealthychineseadults
AT janninegreen phaseirandomizedplacebocontrolledtrialtoevaluatethepharmacokineticssafetyandtolerabilityofnirsevimabinhealthychineseadults
AT theresetakas phaseirandomizedplacebocontrolledtrialtoevaluatethepharmacokineticssafetyandtolerabilityofnirsevimabinhealthychineseadults
AT yuwenjin phaseirandomizedplacebocontrolledtrialtoevaluatethepharmacokineticssafetyandtolerabilityofnirsevimabinhealthychineseadults